Oncology Biosimilars: The Value to Managed Care
On-Demand 1.5-hour Accredited Webcast
Amgen and Coherus BioSciences.
Moderator
Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
Director, Pharmacy Cancer Care
Assistant Professor of Pharmacy
Mayo Clinic
Rochester, Minnesota
Faculty Presenters
Ashley Glode, PharmD, BCOP
Assistant Professor
University of Colorado Skaggs School of
Pharmacy and Pharmaceutical Sciences
Aurora, Colorado
YuQian Liu, PharmD
Director, Specialty Clinical Solutions
Magellan Rx Management
Middletown, Rhode Island
Program Description
The high cost of biologic oncology drugs imposes a substantial burden on the US healthcare system and has created numerous patient access barriers. In recent years, there has been a shift in FDA approvals for biosimilars, with multiple biosimilars for oncology-related supportive care and disease-specific therapeutic indications available on the US market. Managed care pharmacists have a responsibility to educate clinicians and other professionals about the cost-saving benefits associated with oncology biosimilars. These cost-savings may be significant for patient populations affected by socioeconomic challenges or other healthcare disparities that may limit access to treatment. The panelists will discuss the expanded use of oncology biosimilars and strategies managed care professionals can employ to establish clinical pathways and increase biosimilar uptake in clinical practice.
Target Audience: Managed care and oncology pharmacists
Type of Activity: Application
Release date: June 29, 2021
Expiration date: June 29, 2022
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Identify specific examples of how biosimilars may lower the overall costs associated with cancer treatment
- Examine the considerations for incorporating a biosimilar into a managed care formulary
- Illustrate the role of biosimilars in value-based care systems and improving patient outcomes
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-267-H01-P. The activity is available for CE credit through June 29, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Moderator
Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, has the following relevant financial relationships with commercial interests to disclose:
- Grant/Research Support: Janssen, AstraZeneca
- Consultant: AstraZeneca, G1 Therapeutics, Spectrum Pharmaceuticals, Sun Pharmaceutical Industries Ltd
- Speakers Bureau: Pfizer
Faculty
Ashley Glode, PharmD, BCOP, and YuQian Liu, PharmD, have no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy H. Seung, PharmD, BCOP, FHOPA; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.
Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this live CPE activity, please contact:
Privacy Policy and Terms of Use Information:
